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Abstract: The multi-drug resistance of the opportunistic pathogen Acinetobacter baumannii is of
growing concern, with many clinical isolates proving to be resistant to last resort as well as front line
antibiotic treatments. The use of bacteriophages is an attractive alternative to controlling and treating
this emerging nosocomial pathogen. In this study, we have investigated bacteriophages collected
from hospital wastewater in Thailand and we have explored their activity against clinical isolates
of A. baumannii. Bacteriophage vB_AbaM_PhT2 showed 28% host range against 150 multidrug
resistant (MDR) isolates and whole genome sequencing did not detect any known virulence factors
or antibiotic resistance genes. Purified vB_AbaM_PhT2 samples had endotoxin levels below those
recommended for preclinical trials and were not shown to be directly cytotoxic to human cell lines
in vitro. The treatment of human brain and bladder cell lines grown in the presence of A. baumannii
with this bacteriophage released significantly less lactate dehydrogenase compared to samples with
no bacteriophage treatment, indicating that vB_AbaM_PhT2 can protect from A. baumannii induced
cellular damage. Our results have also indicated that there is synergy between this bacteriophage
and the end line antibiotic colistin. We therefore propose bacteriophage vB_AbaM_PhT2 as a good
candidate for future research and for its potential development into a surface antimicrobial for use
in hospitals.
Keywords: Acinetobacter baumannii; antibiotic resistance; Thailand; opportunistic; nosocomial;
bacteriophage; antibiotic alternative; phage therapy
1. Introduction
Acinetobacter baumannii infection has become a research priority due to its exceptional ability
to acquire antimicrobial resistance (AMR) [1,2]. Strains of this Gram negative bacterium have been
shown to have high genetic diversity and large genetic ‘resistance islands’ [3], and there have been
cases of pan-drug resistant isolates that are resistant to all known clinical antibiotics [4]. This has
made A. baumannii a formidable pathogen in the nosocomial environment, particularly against
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immunocompromised and intensive care unit (ICU) patients. Often targeting moist tissues such
as mucous membranes [5], A. baumannii infection will commonly result in urinary tract infections,
meningitis, pneumonia, and wound site infections. Forming strong biofilms, A. baumannii is also
commonly connected with the use of catheters and ventilators [6], the latter of which is associated with
particularly high mortality rates [7].
Current therapies against A. baumannii infections include the beta-lactamase inhibitor sulbactam,
carbapenems, aminoglycosides, and tetracyclines [8]. However, there is no longer an empirical
antimicrobial agent treatment [8] and the extensive use of the broad spectrum carbapenems [9] has led
the World Health Organization to highlight carbapenem resistant A. baumannii as a Class 1: Priority
Critical pathogen for the focus of research and development of novel antibiotics in 2017 [1]. End line
treatment options include tigecycline and colistin [10], both of which have been associated with severe
side effects, including hepatotoxicity, nephrotoxicity, and neurotoxicity [6].
A. baumannii infections are of particular concern in Thailand [11] where this pathogen is the most
common cause of death by AMR associated nosocomial infection [7]. According to NARST (National
Antimicrobial Resistance Surveillance Centre, Thailand), 98% of A. baumannii isolates were susceptible
to the carbapenem imipenem in 1998 [1,12], but by 2002, this had dropped to 79%, and by 2008 only
43% of isolates screened were susceptible. Data collected for 2018 indicated that just over 32% of
A. baumannii isolates in Thailand were susceptible to imipenem and 31.8% to meropenem. In the
same year, only 30.7% of 42,212 isolates were susceptible to sulbactam, 39.1% to the aminoglycoside
gentamycin, and 18.5% to tetracycline [12]. Currently, 97.1% of isolates are recorded to be susceptible
to the last resort treatment, colistin. However, resistance genes to this antibiotic were discovered in
2011 [13] and if the trends follow those seen for the carbapenems, the number of colistin susceptible
A. baumannii isolates could be reduced by two thirds within the next 20 years.
Bacteriophages are an attractive alternative to treating this drug resistant pathogen in the upcoming
‘post antibiotic era’ [14]. The application of lytic bacteriophages could be prepared as a cocktail or as a
combinatorial therapy, thereby reducing the chances of novel resistances being developed [15]. Phage
therapy [16] has been shown to be successful in treating mouse models for A. baumannii pneumonia [17]
and wound infections [18], with the first human trial of bacteriophages being used against A. baumannii
published in 2017 [19]. Gaining regulatory approval for phage therapy is complex and slow however,
and as yet, there are no approved mainstream bacteriophage medicines in the EU or USA. In 2007
though, the Food and Drug Agency (FDA) approved the use of bacteriophages as a food additive to
protect consumers against Listeria monocytogenes in meat [20], and over time, the regulation of phage
therapy may become more straight forward. Until this time, bacteriophages still have the potential to be
utilised for the benefit of human health in hand sanitizers, surface disinfectants, or antimicrobials [21],
and should not be overlooked as a powerful disease control tool. We are only just beginning to touch
on the scope of how bacteriophages could be used in the pursuit of substantial human health benefits.
This study initially investigated five bacteriophages, isolated from hospital wastewater treatment
plants in the lower northern Thai province of Phitsanulok, due to their good host range against
150 multidrug resistant (MDR) A. baumannii isolates [11,22]. A preliminary investigation using 24-h
growth curves indicated that bacteriophage vB_AbaM_PhT2 not only had the highest relative host
range of those screened, but also maintained low A. baumannii turbidity for the longest period of
the five isolates during growth curves. This bacteriophage was therefore carried forward for a
more detailed investigation, with the aim of potentially developing a surface disinfectant. Upon
sequencing of the vB_AbaM_PhT2 genome, there were no known virulence factors or antibiotic
resistance genes found. The treatment of human brain and bladder cell lines with this bacteriophage
produced a significant reduction in relative cytotoxicity caused to the human cells by being grown
in the presence of A. baumannii. There was also an indication of vB_AbaM_PhT2 synergy with
colistin, potentially allowing the clinical dosage of this nephrotoxic drug to be reduced. We therefore
propose vB_AbaM_PhT2 as a candidate for future research and development into a tailored surface
antimicrobial for use in hospitals.
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2. Results
2.1. Acinetobacter baumannii Bacteriophages Present Broad Host Range
Bacteriophages, previously isolated from wastewater at Buddhachinaraj and Bang Rakam
hospitals, were screened against multidrug resistant (MDR) A. baumannii strains [22] from five
tertiary hospitals (HA-HE, see methods) (where MDR-AB is defined as strains resistant to at least three
classes from penicillins/cephalosporins, fluroquinolones, and aminoglycosides [23,24]). The five of
these bacteriophages with the highest host range were carried forward for further investigation in
this study (Table 1 and Figure 1). All five bacteriophages had been previously partially characterised
and were all confirmed to belong to the lytic non-enveloped dsDNA Caudovirales order of viruses via
electron microscopy [25–29] (Supplementary Figure S2). Bacteriophages vPhT2, 4, and 44 were all
Myoviridaes, whereas vPhT29 and 39 were the smaller Podoviridaes. Formerly, these bacteriophages were
published under a different, less standardised nomenclature, but have now been renamed to reflect the
Kropinski system [30] (see methods) for clarity and consistency with other bacteriophage research
(Table 1). These bacteriophages are now called vB_AbaM_PhT2, vB_AbaM_PhT4, vB_AbaP_PhT29,
vB_AbaP_PhT39, and vB_AbaM_PhT44 (previously ØAB02, ØAB04, ØAB29, ØAB39 and ØAB44), but
for the purposes of the flow of the text in this paper, these names have also been abbreviated to vPhT2,
vPhT4, vPhT29, vPhT39, and vPhT44 respectively [30].
Table 1. Overview of properties of Acinetobacter baumannii bacteriophages with broad host ranges.
Bacteriophage AbbreviatedName
Previously Published
Name Host Strain Family
Plaque
Size
vB_AbaM_PhT2 vPhT2 ØAB02 [27,29] A. baumannii AB183 Myoviridae 1 mm
vB_AbaM_PhT4 vPhT4 ØAB04 [27] A. baumannii AB22 Myoviridae 12 mm
vB_AbaP_PhT29 vPhT29 ØAB29 [29] A. baumannii AB20 Podoviridae 2–3 mm
vB_AbaP_PhT39 vPhT39 ØAB39 [29] A. baumannii AB22 Podoviridae 12 mm
vB_AbaM_PhT44 vPhT44 ØAB44 [29] A. baumannii AB20 Myoviridae 2–3 mm
See also Figures S1 and S2.
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Figure 1. Information on host ranges of Thai bacteriophages against 150 multidrug resistantAcinetobacter
baumannii (MDR-AB) strains from five hospitals. From left to right are presented: a UPGMA
(Unweighted Pair Group Method with Arithmetic mean) dendrogram, host susceptibility to isolates
from different hospitals (black = A. baumannii isolates susceptible to bacteriophages (clear plaque),
grey = A. baumannii isolates resistant to the bacteriophages (no plaque), HA–HE = hospitals A–E) and
bacteriophage names and percentage host ranges.
This study showed host ranges of 28.00%, 22.00%, 22.00%, 24.66%, and 25.33% when screened
against 150 MDR A. baumannii for vPhT2, vPhT4, vPhT29, vPhT39, and vPhT44, respectively. Ninety
(60%) of the 150 isolates were killed by at least one of the five bacteriophages. An unweighted pair
group method with arithmetic mean (UPGMA) dendrogram (Figure 1), which was created to represent
the binary clustering of susceptibility of the 150 MDR-AB isolates to the bacteriophages, revealed
that the five bacteriophages could be grouped into two distinct clusters (clusters I and II), based on
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similarities in host range. Cluster I consisted of three bacteriophages (vPhT2, vPhT4, and vPhT39),
whereas vPhT29 and vPhT44 belonged to cluster II.
2.2. Bacteriophage Activity against Their Bacterial Host
2.2.1. Bacteriophages Reduce A. baumannii Turbidity over 24 Hours
In a 24-h growth curve of bacterial samples treated with each bacteriophage at an MOI of 0.01,
there was a brief rise in OD600 (up to ~1.5 to 2.0 h incubation) before a drop in turbidity compared to the
untreated controls (Figure 2). For bacteriophage vPhT44, the OD600 remained low until around 5.5 h,
when it gradually increased again for the rest of the time course. This gradual increase was also seen
for vPhT4, vPhT29, and vPhT39 from around 6.5 h, but for vPhT2, the increase was not until around
nine hours. The OD600 of all samples being treated with bacteriophages remained well below that of
the untreated controls throughout the 24-h incubation period (Table 2). The lowest OD600 readings
over the 24-h period (not including lag phase readings during the first hour) after treatment with
vPhT2, vPhT4, vPhT29, vPhT39, and vPhT44 were observed after 7.0, 4.5, 6.0, 4.5, and 4.5 h respectively
(Figure 2).
Samples of A. baumannii were also treated with apramycin to produce a comparison of changes
in cell turbidity when treated with known antibiotics versus bacteriophages. The turbidity of the
samples treated with apramycin remained low throughout the time course with the lowest OD600
being produced much earlier than the bacteriophage samples, at around 1.5 h, after which there was a
slow but gradual increase.
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Figure 2. Twenty-four-hour growth curve for Acinetobacter baumannii strains grown with and without
bacteriophages or apramycin (500 µg/mL). Data displayed as OD 0 (N = 3).
2.2.2. Bacteriophages Reduce Relative A. baumannii Metabolic Activity over 24 Hours
As a further assessment of relative bacteriophage activity against their host, an endpoint triphenyl
tetrazolium chloride (TTC) assay was performed on growth curve cultures, where the colorimetric
TTC product was a measure of dehydrogenase activity and cell respiration, and was proportional to
bacterial metabolic activity (measured at OD540) (Table 2). A significant reduction in metabolic activity
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(as well as turbidity) was observed for all bacteriophages at 24 h compared to the untreated controls
(where significance was calculated using a two-tailed, paired t-test with a p-value of less than 0.05
being defined as significant). The percentage reduction in relative A. baumannii metabolic activity
(OD540) ranged between 26.27% and 41.04% and turbidity (OD600) was reduced between 39.16% and
67.04%. Bacteriophage vPhT4 produced the greatest reductions in both metabolic activity and turbidity
by 24 h. There was a positive correlation coefficient between turbidity and metabolic activity for all
samples at 24 h (r = 0.95, p < 0.00001).
Table 2. Relative metabolic endpoint activity and turbidity of Acinetobacter baumannii samples treated
for 24 h with bacteriophages or apramycin.
Sample
Relative Metabolic Activity (OD540) 1 Relative Turbidity (OD600)
Average
(OD540 ± SD)
Normalised
(% ± SD)
Significance
of Results 2
Average
(OD600 ± SD)
Normalised
(% ± SD)
Significance
of Results 2
AB20 1.579 ± 0.422 100.00 ± 0.00 N/A 1.863 ± 0.264 100.00 ± 0.00 N/A
AB20 + apramycin 0.006 ± 0.001 0.41 ± 0.110 *** 0.240 ± 0.144 13.47 ± 8.57 ***
AB20 + vPhT29 1.030 ± 0.368 64.89 ± 11.28 *** 1.055 ± 0.338 56.87 ± 16.74 ***
AB20 + vPhT44 1.027 ± 0.326 65.22 ± 11.15 *** 1.119 ± 0.319 59.53 ± 11.51 ***
AB20 + vPhT29 + vPhT44 1.151 ± 0.443 71.52 ± 13.82 ** 1.156 ± 0.262 60.84 ± 8.07 ***
AB22 1.520 ± 0.188 100.00 ± 0.00 N/A 1.811 ± 0.127 100.00 ± 0.00 N/A
AB22 + apramycin 0.009 ± 0.003 0.60 ± 0.28 *** 0.245 ± 0.127 13.56 ± 7.35 ***
AB22 + vPhT4 0.888 ± 0.151 58.96 ± 11.08 *** 0.592 ± 0.170 32.96 ± 10.01 ***
AB22 + vPhT39 0.984 ± 0.198 64.82 ± 11.28 *** 0.695 ± 0.240 38.60 ± 13.92 ***
AB22 + vPhT4 + vPhT39 0.794 ± 0.186 56.19 ± 12.42 * 0.673 ± 0.165 38.16 ± 9.67 **
AB183 1.562 ± 0.186 100.00 ± 0.00 N/A 1.671 ± 0.071 100.00 ± 0.00 N/A
AB183 + apramycin 0.009 ± 0.007 0.560 ± 0.370 *** 0.134 ± 0.061 7.93 ± 3.39 ***
AB183 + vPhT2 0.978 ± 0.306 62.94 ± 20.13 ** 0.832 ± 0.247 49.79 ± 14.19 ***
* p < 0.05, ** p < 0.01, *** p < 0.001, SD = standard deviation, N/A = not applicable. Apramycin concentration
= 500 µg/mL. 1 Relative metabolic activity was calculated from OD540 readings after application of triphenyl
tetrazolium chloride (TTC). 2 Significance was calculated from a two tailed paired t-test compared to the untreated,
bacteria only controls.
2.2.3. Pairs of Bacteriophages Do Not Act Synergistically
Growth curves were also produced using mixes of pairs of bacteriophages that had the same host
(vPhT4 and vPhT39 with AB22 and vPhT29 and vPhT44 with AB20). As before, the relative endpoint
metabolic activity (TTC at OD540) and turbidity (OD600) of the host A. baumannii were analysed (Table 2).
No synergy was detected and so the use of these combinations was not replicated in future testing.
2.2.4. Bacteriophage vPhT2 Presents the Best Performance in all the Parameters Tested
No single bacteriophage performed best in every single assay performed. The relative performance
of bacteriophages across all assays was compared in order to select one for further characterisation
(Table 3). Bacteriophage vPhT2 performed consistently well across all experiments: it maintained a
low A. baumannii OD600 for the longest period in the 24-h growth curves (Figure 2) and had the widest
host range (Figure 1). Bacteriophage vPhT2 was therefore selected for an investigation of its suitability
as a surface antimicrobial or as a potential candidate to be used for phage therapy.
Table 3. Ranking of bacteriophage efficacy and performance across all assays from this study.
Variable vPhT2 vPhT4 vPhT29 vPhT39 vPhT44
Host range 1 1 4 4 3 2
Host metabolism 2 2 1 4 3 5
Host turbidity 3 3 1 4 2 5
Maintaining low host turbidity 4 1 2 3 3 5
Bacteriophages that performed equivalently have been given the same ranking for that variable. 1 Host range
(1 = broadest host range, 5 = narrowest host range). 2 Reduction in relative endpoint host metabolism (OD540 of TTC
assay) after 24 h incubation with the bacteriophage (1 = lowest metabolism, 5 = highest metabolism). 3 Reduction
in endpoint host turbidity (OD600) after 24 h incubation with the bacteriophage (1 = lowest turbidity, 5 = highest
turbidity). 4 Length of time maintaining a low host OD600 during 24-h growth curves (1 = longest, 5 = shortest).
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2.3. Genomic Analysis of vPhT2
2.3.1. Sequencing of the Genome of vPhT2 Phage
Sequencing of the vPhT2 genome revealed a genome size of 166,330 bp, with 246 predicted protein
coding sequences and 9 tRNAs in a single chromosome with an average coverage of 596x (Figure 3,
Table 4) (NCBI accession number: MN864865). The genome was determined to be double-stranded
DNA with a G + C content of 36.4%. Of the 246 predicted open reading frames (ORFs), the majority
genes encoded for proteins with no known function (144 genes) and 102 putative gene products (41%)
were assigned to known functions. Putative proteins encoded by vPhT2 can be categorised into four
groups: structural and morphogenesis (43 proteins), DNA replication/transcription (37 proteins), host
lysis (2 proteins), and ‘other’ (20 proteins) (Figure 3). The major capsid proteins, major and minor
tail proteins, baseplate hub subunit protein, tail fiber proteins and prohead core proteins involved in
structure and morphogenesis were identified, as were the genes involved in DNA replication and
transcription, such as endodeoxyribonucleases, DNA helicases, DNA polymerases, transcriptional
regulators, and RNA ligases. With regards to host lysis by vPhT2, an endolysin and holin lysis
mediator were found. Moreover, a gene coding for a tail-associated lysozyme was found (locus tag:
vB_AbaM_PhT2_173). Additional genes identified coded for a predicted thymidylase synthase, DNA
adenine methylase, acetyltransferase, thymidylate synthase and dihydrofolate reductase (Figure 3).
No known genes involved in antibiotic-resistance and virulence factors were detected in the vPhT2
genome when searched in the virulence factor database (VFDB) [31] and in the antibiotic resistance
genes database (ARDB) [32].
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according to their function (gree = structural and mo phogenesis prot in , blue = DNA r plication
and transcription, red = host lysis, purple = other functions and grey = hypothetical proteins with
unknow function). The genome map was drawn using the BLAST Ri g Image Generator (BRIG)
software, version 0.95, The University of Que nsland, Brisbane, Australia.
2.3.2. Comparison of vPhT2 Genome against the NCBI Database
A BLASTn [33] search against the NCBI database using vPhT2 genome as a query resulted
in the identification of the five most closely related genomes, bTZA1, 101, -1 [34],
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vB_ApiM_fHyAci03 [35] and ZZ1 [36] (Table 4), all of which were Acinetobacter infecting bacteriophages.
At the nucleotide level, the vPhT2 genome was only genetically very similar to Israeli isolate AbTZA1,
where an average nucleotide identity (ANI) of 95.34% was calculated (with a cut-off of >95% to
represent being of the same species). A low ANI (~71–78%) was seen with the next four most similar
bacteriophages, namely AM101, KARL-1, vB_ApiM_fHyAci03, and ZZ1.
Table 4. Comparison between vPhT2 and its most similar genomes in the NCBI database including
pairwise genome comparison ANI-tree similarity matrix compare and gene structure of vPhT2.
Characteristic vPhT2 AbTZA1 AM101 KARL-1 vB_ApiM_fHyAci03 ZZ1
vPhT2 ANI (%) N/A 95.34 78.16 77.45 77.35 71.31
Accession number MN864865 MK278860 MH165274 MH713599 MH460829 HQ698922
Genome size (bp) 166,330 168,223 166,487 166,560 165,975 166,687
GC content (%) 36.4 36.3 36.7 36.8 36.8 34.4
Number of ORFs 246 253 250 253 247 256
Number of tRNAs 9 6 8 0 8 8
Year uploaded 2019 2019 2019 2018 2018 2012
Isolate location Thailand Israel Russia Germany Finland China
Family Myoviridae Myoviridae Myoviridae Myoviridae Myoviridae Myoviridae
Reference This study Unpublished Unpublished Jansen et al. [34] Pulkkinen et al. [35] Jin et al. [36]
ANI = average nucleotide identity, N/A = not applicable, bp = base pairs, ORF = open reading frame.
2.4. Preparations of Bacteriophage vPhT2 Shows Good Stability in Long Term Studies in Lysogeny Broth, but
Not in SM Buffer II
Aliquots of bacteriophage vPhT2 stored in lysogeny broth (LB) or SM buffer II (see methods) at
a number of temperatures and in the presence and absence of light were titred at multiple recovery
points in order to establish the laboratory stability of the suspensions. Bacteriophage suspensions
stored in LB in the fridge (4 ◦C) and at room temperature (21 ± 2 ◦C), both protected from and exposed
to light, did not show a significant reduction in titre during the first 14 days of storage (Table 5 and
Supplementary Table S2). When the samples were stored in SM buffer II however, a reduction in titre
was seen almost immediately with reductions of 1.57 ± 0.03, 1.87 ± 0.04 and 1.92 ± 0.21 log10PFU/mL
after only eight days at 4 ◦C, 21 ◦C without light, and 21 ◦C with light respectively (Figure 4). This
degradation continued over the rest of the time course, with a greater than 2.5 log reduction being seen
after 14 days storage for all three samples. When stored in LB in the fridge during an extended study
over 10 months, only a 1.30 ± 0.08 log10PFU/mL reduction in bacteriophage titre was seen in this time
(data not shown here). When comparing the room temperature samples (21 ◦C) kept in the dark with
those exposed to light, there was no significant difference in titre of samples stored in SM buffer II seen
at any time point for 14 days (p > 0.05).
Table 5. Logarithmic reduction in bacteriophage vPhT2 after storage in SM buffer II or LB for 14 days
in different temperature and light conditions.
Storage Location Storage
Reagent
Reduction in Titre (log10PFU/mL ± SD)
1 Day 3 Days 8 Days 14 Days
Fridge (4 ◦C) SMII NR 0.66 ± 0.00 1.57 ± 0.03 2.60 ± 0.29
Room temperature (21 ◦C) SMII 0.32 ± 0.01 0.79 ± 0.18 1.87 ± 0.04 2.94 ± 0.33
Room temperature with light (21 ◦C) SMII 0.32 ± 0.04 0.68 ± 0.03 1.92 ± 0.21 2.75 ± 0.10
Freezer (−20 ◦C) SMII 1.99 ± 0.09 2.74 ± 0.01 3.59 ± 0.18 4.23 ± 0.06
Biological incubator (37 ◦C) SMII 0.79 ± 0.14 1.58 ± 0.06 3.88 ± 0.07 4.88 ± 0.21
Fridge (4 ◦C) LB NR NR NR NR
Room temperature (21 ◦C) LB NR NR NR NR
Room temperature with light (21 ◦C) LB NR NR NR NR
PFU = plaque forming units, SD = standard deviation, NR = no significant reduction (p > 0.05), LB = lysogeny
broth, SMII = SM buffer II (see methods).
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Figure 4. Logarithmic titre of vPhT2 after storage in SM buffer II or LB for 14 days in different
temperature and light conditions compared to day zero. (NS = no significance, * p < 0.05, ** p < 0.01,
*** p < 0.001).
For samples stored in SM buffer II in the freezer (−20 ◦C), there was already a 1.99 ± 0.09
log10PFU/mL reduction in titre after only 24 h, compared to time zero (p < 0.05) (Table 5). This then
followed with log reductions of 2.74 ± 0.01, 3.59 ± 0.18 and 4.23 ± 0.06 log10PFU/mL by three (3), eight
(8) and fourteen (14) days storage compared to time zero. Storage at 37 ◦C in SM buffer II resulted in
the greatest degradation of vPhT2, with a significant reduction in titre of 0.79 ± 0.14 log10PFU/mL seen
after 24 h (p < 0.05). By three days this was a 1.58 ± 0.06 log10PFU/mL reduction and by eight and
14 days this was 3.88 ± 0.07 and 4.88 ± 0.21 log10PFU/mL, respectively.
2.5. vPhT2 Activity in the Human Cell Environment
2.5.1. CsCl Purified vPhT2 Preparations Had Low Endotoxin Levels
Bacteriophage vPhT2 was purified via a caesium chloride gradient prior to testing in the human
cell environment (and stability testing trials) in order to minimise the number of endotoxins in the
preparation. A 1 × 108 PFU/mL sample of CsCl purified vPhT2 in SM buffer II was found to have 10.92
endotoxin units per millilitre (EU/mL) (Table 6). Crude lysates containing vPhT2 in LB had endotoxin
levels above the threshold of the assay.
Table 6. Data on units of endotoxins measured in bacteriophage preparations.
Sample Sample Concentration EU/mL
Crude vPhT2 in LB 5 × 105 PFU/mL Above threshold of standard curve
Purified vPhT2 in SM buffer II 1 × 108 PFU/mL 10.92
LB medium N/A 0.09
SM buffer II N/A 0.03
Leibovitz medium N/A 0.05
PFU = plaque forming units, EU = endotoxin unit, LB = lysogeny broth.
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2.5.2. vPhT2 Presents No Cytotoxicity to Human Cell Lines
Lactate dehydrogenase is an enzyme found in nearly all living cells and catalyses the production
of pyruvate from lactate and back again, producing NAD+ and NADH [37]. As an intracellular enzyme,
the extracellular presence of LDH in a supernatant is an indicator of cytotoxicity, human cell line death
and damage. Treatment of T24 and hCMEC/D3 cell lines with bacteriophage vPhT2 (in the absence of
A. baumannii) produced no significant difference (p > 0.05) in LDH release compared to cell lines that
had not been treated, indicating that this bacteriophage was not cytotoxic (Table 7). All human cell
lines had a significant increase (p < 0.05) in levels of LDH released after treatment with A. baumannii (in
the absence of bacteriophages) compared to no bacterial infection (Table 7), indicating that the presence
of A. baumannii was cytotoxic.
Table 7. Raw data for lactate dehydrogenase levels (OD490–OD680) released by different human cell
lines treated with Acinetobacter baumannii or vPhT2 compared to no treatment.
Human Cell Line
Average Relative LDH Release (OD490–680 ± SD)
Human Cells Only Human Cells and vPhT2 Human Cells and AB183
T24 0.185 ± 0.012 0.204 ± 0.011 2.444 ± 0.057
hCMEC/D3 0.017 ± 0.002 0.022 ± 0.004 0.486 ± 0.125
LDH = lactate dehydrogenase, SD = standard deviation.
2.5.3. vPhT2 Reduces LDH Production by Human Cell Lines Grown in the Presence of A. baumannii
When vPhT2 was applied to human cell lines that had been exposed to A. baumannii for an hour,
there was a 90.98 ± 0.49% and 84.01 ± 1.74% reduction in LDH production over the next 23 h by T24
and hCMEC/D3 cells, respectively (p < 0.001) (Figure 5).
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2.5.4. vPhT2 Reduces A. baumannii Activity in the Presence of Human Cell Lines
As a marker of bacterial inhibition, the endpoint turbidity (OD600) and titres of A baumannii
from samples of the LDH assay were measured. The reduction in OD600 for the supernatant of the
human cell lines exposed to A. baumannii and vPhT2 was 85.19% ± 4.85% and 89.35% ± 1.72% for
T24 and hCMEC/D3 cells respectively, compared to samples only treated with A. baumannii (Table 8)
(p < 0.001). There were also measured to be log reductions in A. baumannii titre of 3.34 ± 0.11 and 3.08
± 0.13 log10CFU/mL when treated with vPhT2 in the presence of T24 and hCMEC/D3 cells respectively
(Table 8). Unsurprisingly, there was a positive correlation between relative LDH levels produced by
the human cell lines and the reduction in A. baumannii OD600, (r = 0.52, p < 0.00001) or endpoint titre
(r = 0.67, p < 0.001). As A. baumannii growth was reduced, so were the levels of LDH released by
human cell lines.
Table 8. Raw data for Acinetobacter baumannii turbidity (OD600) and titre (log10CFU/mL) from samples
grown in the presence of human cell lines.
Human Cell Line
Average OD600 (±SD) Average log10CFU/mL (±SD)
Human Cells and
AB183
Human Cells,
AB183 and vPhT2
Human Cells and
AB183
Human Cells,
AB183 and vPhT2
T24 1.051 ± 0.040 0.156 ± 0.051 9.47 ± 0.01 6.13 ± 0.11
hCMEC/D3 0.989 ± 0.073 0.105 ± 0.017 9.46 ± 0.07 6.38 ± 0.13
CFU = colony forming units, SD = standard deviation.
2.6. vPhT2 Works Synergistically with Colistin
Host strainA. baumanniiAB183 was shown to be susceptible to colistin (EUCAST clinical breakpoint
>2 µg/mL [38]) (Supplementary Table S3 and Figure S4) with a measured MIC of 1 µg/mL. Previous
studies have indicated that endolysins from A. baumannii bacteriophages can work synergistically
with colistin [27]. When colistin and bacteriophage vPhT2 were tested in combination against AB183,
a fractional inhibitory concentration index (FICI) value of 0.35 was calculated (Table 9), indicating
synergy between this bacteriophage and colistin (where the FICI was interpreted as follows: FICI ≤ 0.5,
synergy; <2 and >0.5, indifference; ≥2, antagonism [39]).
Table 9. Susceptibility of Acinetobacter baumannii host strain AB183 to colistin in combination with
bacteriophage vPhT2.
Treatment Independent MIC Value Combined MIC Value FIC Values
Colistin 1 µg/mL 0.25 µg/mL 0.25
vPhT2 500 PFU/mL 50 PFU/mL 0.1
FICI 0.35
MIC = minimum inhibitory concentration, FIC = fractional inhibitory concentration, FICI = fractional inhibitory
concentration index (calculated FICI = combined MIC/independent MIC), PFU = plaque forming units.
3. Discussion
The five bacteriophages in this study had a host range of between 22% and 28% of 150 MDR
A. baumannii isolates. When analysing host range data and discussing the ‘broadness’ of the range,
the diversity of location sources of the hosts should be taken into consideration [40]. Bacteriophages
isolated from hospital waste-water are more likely to be efficacious against clinical isolates from the
same hospital or region than independent sources, due to coevolution [28,29]. The A. baumannii isolates
screened in this study were from five hospitals spread across Thailand, a country of over 500,000 km2
with a population of around 70 million inhabitants [41]. Hospitals were chosen to be representative
of a range of different environments including industrial and rural areas, international borders, the
presence of tourists and foreign workers, as well as geographic locations and regional climates. All five
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bacteriophages were from two hospitals in lower northern Thailand. Thus, the bacteriophages appear
to have the potential to be used in a range of Thai hospital locations and possibly the rest of the world.
In fact, a screen of the NCBI database [33] showed vPht2 to be of the same species (% ANI > 95) as a
bacteriophage isolated from Israel, AbTZA1 (accession number: MK278860). Groupings produced by
the UPGMA dendogram, also revealed that there are two groups of bacteriophage host ranges within
the five bacteriophages screened. If applied as a cocktail of cluster I (vPhT2, vPhT4, vPhT39) and II
(vPhT29 and vPhT44), the overall host ranges could be expected to be higher [29]. In fact, 60% (90 out
of 150) of the clinical isolates were killed by at least one of the five bacteriophages.
Over the course of a 24-h growth curve, the OD600 of samples treated with the bacteriophages
did not increase past 60.84% of the negative controls. Although there was a significant reduction
in host turbidity by all bacteriophages at all-time points analysed, bacteriophage vPhT4 produced
the greatest relative reductions in A. baumannii metabolic activity (TTC assay) and turbidity (OD600),
whereas bacteriophage vPhT2 maintained the low OD600 for the longest period (nine hours compared
to 5.5–6.5 h for all others). Bacteriophage vPhT2 also had the highest host range and for this reason
was selected for further investigation and characterisation.
The production of sequencing data on vPhT2 means there is now the option for the genetic
engineering of this bacteriophage, which could potentially lead to the optimisation of its use for
multiple commercial applications. An analysis of the vPhT2 genome showed that it contained the
gene to carry a lysozyme domain fused to its tail, suggesting that this bacteriophage encodes enzymes
capable of degrading host’s cell wall at the phage’s first contact with the cell surface and the last step
of the phage lytic cycle [42]. As the genome did not harbour any known virulence and antibiotic
resistance genes that could potentially confer to a host, it shows promise as a suitable candidate for
further applications in phage therapy.
Stability and a sensible shelf-life are important for the accessibility and usefulness of an antibacterial
product in the clinical environment. Any specific storage conditions could complicate existing hospital
procedures and possibly lead to incorrect usage by untrained individuals. It is promising therefore
that the vPhT2 titre was stable at room temperature, the most likely routine storage temperature for a
disinfectant, when stored in LB (both in the presence and absence of light) for 14 days. After 10 months
in the fridge in this same diluent, there was just over a one log reduction in vPhT2 titre, indicating that
this is a possible long-term storage option. However, lysogeny broth is not a common commercial
storage medium for bacteriophages and it is unclear why the bacteriophage was less stable in SM buffer
II. Further investigation is therefore required to find a more suitable, commercially relevant diluent for
vPhT2. We also suggest the use of an opaque storage vessel in order to protect the long-term efficacy of
bacteriophage suspensions.
Endotoxins are part of the outer membrane of the cell wall of Gram negative bacteria and
are a known pyrogenic contaminant of injectable drugs [42]. Endotoxin levels for purified vPhT2
(1 × 108 PFU/mL) were shown to be below the threshold of 200 EU/mL as proposed by Brito et al. for
endotoxin levels in live attenuated vaccines going through preclinical trials, based on United States
Pharmacopoeia (USP) advice [42,43]. Should a higher dose or volume be required, endotoxin levels for
dosages up to almost 20 times higher would still be below these guideline amounts and well within
the USP recommendation of 5 EU/kg/hr [44].
The treatment of human T24 bladder and hCMEC/D3 brain cell lines with A. baumannii and vPhT2
resulted in a significant reduction in cytotoxicity (as measured by relative LDH levels) compared to
when no bacteriophage was present. In addition, neither human cell line grown in the presence of
vPhT2 (with no A. baumannii) released significantly more LDH than controls grown without exposure
to bacteriophages indicating that vPhT2 is not cytotoxic.
Previous trials with purified A. baumannii bacteriophage endolysins showed broad range host
activity and synergy with colistin [27]. The polymyxin colistin, with all its associated side effects, is one
of the end line treatments for A. baumannii infection. With an FICI of 0.35, the indication that colistin
can work synergistically with bacteriophage vPhT2 is very promising. Developing vPhT2 for use in
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the clinical environment, for example through developing an encapsulated delivery system [45] or
further stability trials are therefore to be considered as the next steps for bacteriophage vPhT2.
4. Materials and Methods
4.1. Collection of Samples and Host Range Analysis
Seventeen bacteriophages were isolated from wastewater at Buddhachinaraj and Bang Rakam
hospitals in Phitsanulok province, Thailand in 2010 and were screened against 150 MDR A. baumannii
strains collected from five hospitals [11,22,27,29] using a spot test method as described previously [27].
For additional information on the chosen bacteriophages and MDR-AB, please refer to the supplement
file: ‘Selected-MDRAB-150-isolates’. The first hospital (HA) was located in central Thailand, another
one was in the lower northern region (HB), another one was on the northern tourist border with
Myanmar (HC), one was located in an eastern industrial area with a high population of foreign
workers (HD) and the final hospital was in northern Thailand (HE). Each hospital had between 405 and
1000 beds at the time of the study and isolates were collected from a range of different departments
and specimen types.
Colonies of A. baumannii were suspended in 0.85% NaCl to an equivalent of a 0.5 McFarland
standard (1 × 108 CFU/mL). The suspension was then swabbed on to Trypticase Soy Agar (TSA) to
create a bacterial lawn. Phage suspensions (2 µL at 1 × 108 PFU/mL) were dropped into the lawn
before plates were incubated at 37 ◦C for eight (8) hours to allow cell lysis. Bacterial clearance at the
site of bacteriophage inoculation implied that the host was sensitive to that particular bacteriophage.
All experiments were performed in duplicate.
Of the five bacteriophages with the highest host range, bacteriophages vPhT4 and vPhT39 were
tested against the chosen A. baumannii host strain AB22, vPhT29 and vPhT44 against the host strain
AB20 and vPhT2 against the host strain AB183 (Table 1, Supplementary Figure S1 and Table S1) due
to the good titres seen for these bacteriophage-host pairs in initial screening studies. Bacteriophage
vPhT2 also showed some specificity against host strain AB22. Bacteriophages vPhT2, 4, 39 and 44 were
all isolated from Buddhachinaraj hospital whereas vPhT29 was from Bang Rakam hospital. Hosts for
propagating these bacteriophages were isolated from two different hospitals, one in northern Thailand
and another in central Thailand (Supplementary Table S1) and cultivated in LB and LBA (lysogeny
broth agar) (1.5% agar) as described previously [29].
4.1.1. Analysis of Host Range Data
A UPGMA dendrogram was created using DendroUPGMA: a dendrogram construction utility
website using the default settings [46]. The input query was for a binary outcome (yes or no). If a
particular bacteriophage could infect an A. baumannii host, then it was given a rating equal to one (yes),
and if it could not infect, it was given a rating equal to zero (no).
4.1.2. Naming of the Bacteriophages
The five bacteriophages were renamed (Table 1) for this study according to Kropinski system [30]
to make their referencing and entry into open access databases more consistent with contemporary
and progressive research. The prefix of vB_AbaM_PhT or vB_AbaP_PhT was used to indicate that
these were bacterial viruses (vB), infecting A. baumannii (Aba), were either Myoviridaes or Podoviridaes
(M or P) and were isolated from Phitsanulok province in Thailand (PhT). This nomenclature system
was not used in previous publications with these bacteriophages as they were first isolated only a year
after the Kropinski system was first suggested in 2009 and knowledge of this nomenclature was not
widespread or commonly practiced.
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4.2. Bacteriophage Characterisation
4.2.1. Viral Enrichment—Propagation of Bacteriophages of Interest
To propagate the bacteriophage isolates, the A. baumannii hosts were grown overnight in LB
(Sigma-Aldrich: Lennox—10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl) at 37 ◦C and 130 rpm.
In the morning, 1 mL of the overnight liquid culture was used to inoculate 50 mL fresh LB. This was
then incubated at 37 ◦C and 130 rpm until an OD600 of 0.3 was reached. At this point, 100 µL of
bacteriophage stock was added to each flask and samples were incubated for a further four hours.
Bacterial debris was pelleted by centrifugation at 3220 g for 10 min before the supernatant was passed
through a 0.2 µm pore size membrane filter. The prepared phage stocks in LB were stored at 4 ◦C.
Bacteriophage samples stored in LB were used for initial 24-h growth curve assays, stability trials, and
other bacterial studies.
4.2.2. Caesium Chloride Purification of Bacteriophages
Bacteriophages were propagated as described above, with the assay being scaled up to a 250 mL
sample. Sodium chloride was added to samples to a final concentration of 1 M. After incubation on ice
for one hour, samples were centrifuged at 3220× g and the supernatant passed through a 0.2 µm pore
size membrane filter before PEG8000 was added to a final concentration of 10% w/v. This was then left
overnight at 4 ◦C, before the samples were centrifuged at 25,000× g for 60 min. The phage pellet was
then resuspended in 6–7 mL SM buffer I (1 M NaCl, 8 mM MgSO4 · 7H2O, 25 mM Tris-HCl pH 7.5)
and passed through a 0.2 µm pore size membrane filter before undergoing concentration and further
purification in a CsCl gradient for 20 h at 150,000× g and 4 ◦C. The extracted phage band was then
dialysed first in SM buffer I and then twice with SM buffer II (100 mM NaCl, 8 mM MgSO4 · 7H2O,
25 mM Tris-HCl pH 7.5) in order to remove the CsCl. The purified phage was then stored at 4 ◦C (see
stability trials, Section 2.4). Bacteriophage samples stored in SM buffer II were used in human cell
assays and stability trials. Samples were processed promptly due to their instability in SM buffer II.
4.2.3. Plaque Assay—Quantification of Bacteriophages of Interest
Bacteriophage titre was determined via a soft agar plaque assay, using 0.7% agar top LBA [47].
One hundred microliters of serially diluted bacteriophage were incubated with 100 µL host cells
(1 × 108 CFU/mL) at room temperature for 15 min before 3 mL molten top agar was added and poured
over a 90 mm 1.5% agar LBA plate. Plaques were quantified after overnight incubation at 37 ◦C. For
spot/drop tests, 100 µL host cells (1 × 108 CFU/mL) were added to molten 0.7% LBA, poured over a
1.5% agar LBA plate, and allowed to set before 5 µL bacteriophage (1 × 109 PFU/mL) or 5 or 10 µL
antibiotic were spotted onto the surface and allowed to dry.
4.2.4. Classification of Bacteriophage Family
Bacteriophage families were classified as previously described, using electron microscopy [27,29,48].
4.3. Bacterial Host Characterisation
Antibiotic Susceptibility and MIC Testing
An initial screen of antibiotic susceptibilities was done using a drop test, where 10 µL of different
antibiotics were spotted onto a lawn of A. baumannii on LBA. To determine if the three A. baumannii
host strains were multi, extensively or pan drug resistant, the more quantitative disc diffusion method
was carried out on selected clinically relevant antibiotics according to CLSI guidelines [49]. A further
investigation into the colistin, apramycin, tigecycline, and meropenem resistance profiles of the
A. baumannii host strains, was performed according to broth microdilution methods outlined by
EUCAST [50] using cation adjusted Mueller Hinton broth 2 (CA-MHB) (Sigma-Aldrich—17.5 g/L acid
hydrolysate of casein, 3 g/L beef extract, 1.5 g/L starch) and an initial inoculum of 5 × 105 CFU/mL.
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The CA-MHB used with tigecycline was either used fresh (<12 h) or frozen and used later, in order to
optimise the activity of this antibiotic, which can be negatively impacted by media that has been stored
for too long [10].
4.4. Bacteriophage Activity against the Bacterial Host
4.4.1. Twenty-Four-Hour A. baumannii Growth Curves
A total load of 1 × 107 CFU A. baumannii hosts were added to each of the wells of a 96 well plate
(5 × 107 CFU/mL). Bacteriophages were added to a MOI of 0.01 (final load of 5 × 105 CFU/mL) (total
volume = 200 µL). Samples were grown in LB at 37 ± 2 ◦C shaking in a plate reader with measurements
of the optical density (OD600) taken every five minutes over a 24-h period. Additional MOIs were also
tested in the MOI optimisation growth curve assay (Supplementary Figure S3a–e).
4.4.2. Triphenyl Tetrazolium Chloride Assay
After the 24 h growth curve, OD600 readings were completed, 50 µL of each sample was added
to 150 µL water, and 50 µL 0.1% triphenyl tetrazolium chloride (TTC, Sigma-Aldrich) was diluted
in LB and samples were incubated statically at 37 ◦C for three hours [48]. At this point the OD540
was measured, with the red coloured product being used as an indicator of relative metabolism.
All tests were carried out with biological triplicates, with triplicate technical replicates assayed each
time. Apramycin (final concentration of 500 µg/mL) was used as a positive control during this assay
(a non-clinically relevant antibiotic was selected due to the host strains being resistant to most clinically
relevant antibiotics trialled) (Supplementary Figure S4). A statistical analysis of results was carried out
with Microsoft Excel using a two-tailed paired t-test, with a p-value of less than 0.05 being used as the
threshold for significance.
4.5. Whole Genome Sequencing and Bioinformatics Analysis
Extraction and purification of bacteriophage genomic DNA was performed from on a high titre
phage lysate (109 PFU/ml) using a phenol:chloroform method as previously described [47]. An Illumina
sequencing library was generated with the Nextera XT DNA library preparation kit, following the
manufacturer’s instructions. Sequencing was performed on an Illumina MiSeq (250 bp paired-end).
The resultant reads were trimmed with Sickle version 1.33 using default settings [51], prior to being
assembled with SPAdes version 3.6.0 using the “–only-assembler” option [52]. The resulting single
contig was annotated with Prokka version 1.11 using a custom database constructed from proteins
of all current viral genomes [53]. The genome sequence of the selected bacteriophage was deposited
in GenBank [33] under accession number MN864865. The annotated ORFs were searched by using
BLASTn to detect virulence and antibiotic resistance genes in the virulence factor database (VFDB) [31]
and antibiotic resistance genes database (ARDB) [32]. Hits with more than 75% coverage and 50%
identity were considered as positive results.
To compare the vPhT2 with other bacteriophages, a BLASTn search with the vPhT2 genome
against the NCBI database was performed and the most similar genomes were selected for further
study [33]. The average nucleotide identity (ANI) percentages, based on BLAST pairwise sequence
alignments, of these bacteriophage genomes were calculated using JSpeciesWS version 3.2.6 [54] with
the default settings. An ANI of above 95% was classed as an indicator of two genome being from
the same species [55]. The circular map of the bacteriophage genome was generated through the
BLAST Ring Image Generator (BRIG) program, version 0.95, written by Alikhan et al., Australian
Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University
of Queensland, Brisbane, QLD 4072, Australia [56].
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4.6. Stability Trials
Aliquots of propagated bacteriophage were stored in the fridge (4 ◦C), at room temperature (21 ◦C,
both protected and exposed to light), at 37 ◦C and in the freezer (−20 ◦C) in LB or SM buffer II for
14 days. Samples were taken after one, three, eight and 14 days storage and were quantified using the
plaque assay described above and tested in duplicate. Aliquots stored in the freezer only underwent
one freeze/thaw cycle each. Additional aliquots of samples suspended in LB were also kept in the
fridge for 10 months to provide data on longer term storage in this location. Samples were plated in
duplicate and reductions in titre were calculated as PFU/mL and log10PFU/mL compared to samples
from time zero.
4.7. Bacteriophage Activity in the Human Cell Environment
4.7.1. Endotoxin Testing
The presence of endotoxins in purified bacteriophage samples was measured using the Limulus
Amebocyte Lysate (LAL) Chromogenic Endpoint Assay Kit from Hycult Biotech, according to the
protocols supplied with the kit.
4.7.2. Lactate Dehydrogenase Cytotoxicity Assay
Human cell lines for this study were T24 urinary bladder epithelial cells (ATCC® HTB-4™) and
hCMEC/D3 blood brain barrier endothelial cells (Sigma Aldrich SCC066). Cytotoxicity to human cells
was measured using the Invitrogen™ CyQUANT™ LDH Cytotoxicity Assay Kit, according to the
protocols supplied with the kit.
Human cell lines were grown up at 37 ◦C in their own cell specific media with 5% CO2 until they
reached a suitable level of confluency. Cells were then trypsinised and resuspended in Leibovitz media
(Sigma-Aldrich) with 5% FBS (Gibco) to a final concentration of 400,000 cells/mL. One millilitre of
this suspension was then added to the wells of six well plates and grown overnight at 37 ◦C (no CO2
supplementation). On the same day, an overnight culture of A. baumannii was started in Leibovitz
media + 5% FBS. Bacteriophages were diluted in LB to a final concentration of 1 × 109 PFU/mL. After
24 h growth, 800 µL of A. baumannii overnight culture (with refreshed medium) or 800 µL Leibovitz
medium + 5% FBS were added to the human cell lines and incubated at 37 ◦C for one hour. After an
hour, 200 µL host specific bacteriophage or 200 µL LB medium was added to relevant samples (final
bacteriophage concentration of 1 × 108 PFU/mL). The total volume per well of the six well plates was
2 mL. Samples were then incubated for a further 23 h at 37 ◦C. After this incubation, aliquots were
taken from each sample and the OD600 measured, as an indicator of A. baumannii turbidity. A second
set of aliquots was taken in order to titre the CFU/mL of A. baumannii present, as a measure of host
bacteria viability. A third set of aliquots was also taken and centrifuged at 17,000× g in a microfuge
for five minutes to produce a cell pellet. Fifty microliters of the supernatant were then transferred to
the wells of a 96 well plate in triplicate before adding 50 µL LDH assay test solution. Samples were
mixed by tapping the side of the plate and then covered with foil to protect them from light during a
30-min incubation at room temperature. As a control, 200 µL lysis buffer supplied with the kit was
added to relevant samples 45 min prior to adding LDH test solution. Fifty microliters of stop solution
were added to all samples before measuring the optical density (OD) at 490 and 680 nm. Relative
cytotoxicity to human cell lines was calculated from OD490 minus OD680. All tests were carried out
with triplicate biological replicates. A statistical analysis of results was carried out with Microsoft
Excel using a two-tailed un-paired t-test, with a p-value of less than 0.05 being used as the threshold
for significance.
4.8. Synergy Trials
Synergy trials between colistin and bacteriophage vPhT2 were carried out using A. baumannii
AB183 in a checker-board assay, following the same set up methods as the MIC testing, according
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to the EUCAST broth microdilution methods [50]. Synergy of colistin with the bacteriophages was
determined from fractional inhibitory concentration (FIC) values, where a FIC is the MIC for an agent
working in combination divided by the MIC of an agent when working alone. If the sum of the
FIC values for both agents is ≤0.5, then this indicates synergy, whereas a ΣFIC > 0.5 and <2 shows
indifference, and a value ≥2 indicates the antagonism of two agents against each other [39].
5. Conclusions
Understanding the in vivo activity of bacteriophages against their host bacteria is the first step
in the successful development of a commercial or clinical product. In this study, the performance
of a broad host range bacteriophage was analysed against its A. baumannii host and in the presence
of human cell lines through the use of growth curves, bacterial viability assays, cytotoxicity studies,
whole genome sequencing, stability testing, and assaying for synergy with colistin. Bacteriophage
vPhT2 has shown potential to be made into a safe hand sanitizer or antimicrobial for use in hospitals,
showing promise for development into a phage therapy tool in the future.
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